The American Medical Association (AMA) has recently introduced a new Current Procedural Terminology (CPT) code, specifically for the Imagio Breast Imaging System developed by Seno Medical.
This system caters to those in the field of breast cancer diagnosis. It employs a combination of laser optics, sound, and artificial intelligence to create both functional and anatomical images of the breast.
This technology, known as opto-acoustic (OA/US) imaging, distinguishes itself by generating detailed blood maps around breast masses through opto-acoustic images, while simultaneously providing conventional anatomical visuals via ultrasound.
This dual approach aids in the detection of cancer by identifying two key indicators: angiogenesis (the formation of new blood vessels) and deoxygenation (reduced oxygen levels), which are common traits of malignant tumors.
The company claims a notable advantage of the Imagio OA/US system over traditional imaging methods is its ability to conduct these assessments without subjecting patients to the risks associated with ionizing radiation (found in X-rays) or the need for contrast agents.
The newly issued CPT code, 0857T, falls under the Category III codes, which are assigned to emerging technologies, services, and procedures. Effective from January 1, 2024, this code allows healthcare providers, including physicians and imaging centers, to seek reimbursement for the use of this opto-acoustic technology in diagnosing breast cancer.
The introduction of this code is a crucial step in integrating the Imagio system into standard patient care, enabling healthcare facilities to more readily adopt this advanced diagnostic tool.
Seno Medical, based in San Antonio, Texas, specializes in the development and commercialization of opto-acoustic imaging for cancer diagnosis.
Since its FDA approval in January 2021, with a subsequent approval in June 2022 for its latest ultrasound technologies, Seno Medical’s Imagio Breast Imaging System has been recognized for merging opto-acoustic technology with ultrasound to provide real-time, functional, and anatomical images of the breast without the harmful effects of radiation.
The company’s efforts have been acknowledged with the 2023 Enabling Technology Leadership award by Frost & Sullivan, highlighting its innovative contributions to diagnostic imaging.
Seno Medical’s collaboration with The Pinnacle Health Group aims to support healthcare professionals and patients in navigating the coding and claims process for the new CPT code, further facilitating the adoption of this groundbreaking technology in breast cancer diagnosis.
